Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVA-LTE long-term safety extension of mavacamten in adults with hypertrophic cardiomyopathy
2018-004039-64Phase 3Unknown
- Sponsor
- MyoKardia
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (2 cohorts), sponsored by MyoKardia. Primary endpoint: Long-term safety and tolerability of mavacamten. Status: unknown.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2018-004039-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004039-64.